Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma

Imexon [AOP99.0001 (4-imino-1,3-diazobicyclo[3. 1. 0]-hexan-2-one)] belongs to a novel class of promising anticancer agents that induce tumor apoptosis through oxidative stress. Clinical experience since the late 1960s has provided initial evidence for a clinical antitumor activity. Our open-label, multicenter phase I clinical trial was designed to further investigate the adverse event (AEs) profile and pharmacokinetics of AOP99.0001 in pretreated myeloma patients and collect initial data on the potential clinical efficacy in this indication. Thirty-six patients with relapsed or refractory myeloma, who had been pretreated with at least two lines of therapy earlier, were included. Imexon was applied intravenously on 5 consecutive days for 2 weeks (d1-5 and d8-12) for a 3-week cycle. The plasma half-life of AOP99.0001 and its active metabolite AOP99.0002 was found to be approximately 1.2 and 2.6 h, respectively. The mean duration of treatment with Imexon was 6.8 weeks in a dose range between 50 and 1000 mg/m2 without reaching dose-limiting toxicity. Drug-related AEs occurring with a frequency of greater than 10% were fatigue, nausea, constipation, headache, asthenia, anemia, thrombocytopenia, leukopenia and creatinine increase. A total of nine severe adverse events occurred in three patients. No mortality was encountered when patients were on treatment with Imexon. Preliminary antimyeloma efficacy of AOP99.0001 was observed with 1 minimal response, 12 (36%) stable disease responses, and all other evaluable patients had progressive disease. Remarkably, the patient with minimal response also experienced a complete clinical resolution of myeloma-associated polyneuropathy. Overall, Imexon was safe and well tolerated in the dose range investigated. Imexon showed minor clinical activity as a single agent in heavily pretreated myeloma patients. On account of its unique mechanism of action, favorable toxicity profile, initial clinical evidence for antimyeloma activity, and its known synergistic activity in combination with approved agents for myeloma treatment, AOP99.0001 is recommended for future clinical studies in combination regimens in multiple myeloma.

[1]  C. Ng,et al.  A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer , 2010, Investigational New Drugs.

[2]  B. Barlogie,et al.  Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. , 2009, Blood.

[3]  M. Dimopoulos,et al.  Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG) , 2009, Leukemia.

[4]  Axel Benner,et al.  Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. , 2008, Blood.

[5]  D. Dingli,et al.  Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.

[6]  S. O’Day,et al.  Phase I trial of imexon in patients with advanced malignancy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Dorr,et al.  Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines , 2007, Cancer Chemotherapy and Pharmacology.

[8]  L. Gordon,et al.  Imexon-Induced Apoptosis in Multiple Myeloma Tumor Cells Is Caspase-8 Dependent , 2004, Clinical Cancer Research.

[9]  H. Goldschmidt,et al.  Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. , 2001, Blood.

[10]  M. Briehl,et al.  Induction of mitochondrial changes in myeloma cells by imexon. , 2001, Blood.

[11]  M. Micksche,et al.  Antitumor activity of imexon. , 1995, Journal of the National Cancer Institute.

[12]  E. Hersh,et al.  Sensitivity of multiple myeloma to imexon in the human tumor cloning assay. , 1994, Journal of the National Cancer Institute.

[13]  A. Evens,et al.  Oxidative stress and apoptosis: a new treatment paradigm in cancer. , 2006, Frontiers in bioscience : a journal and virtual library.

[14]  M. Chirigos Immune modulation and control of neoplasia by adjuvant therapy , 1978 .